ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: St. Jude, Yale to Get Bristol-Myers Grants; Five Named for New Young Scientists Awards

May 6, 1988

Broder To Leave In March; Sondik To Be Acting Director

January 27, 1995

Cause Of Allergic Reaction To Cetuximab Found

March 28, 2008

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

Upton Says NCI Must Take “Vigorous Role” In Prevention

February 3, 1978

OSU Continues As comprehensive Center; City Of Hope BMT Program Wins 5-Year Grant.

July 14, 2000